Literature DB >> 28978711

Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.

Syna Kuriakose Gift1, Daniel P Leaman1, Lei Zhang1, Arthur S Kim1, Michael B Zwick2.   

Abstract

The trimeric envelope glycoprotein spike (Env) of HIV-1 is the target of vaccine development to elicit broadly neutralizing antibodies (bnAbs). Env trimer instability and heterogeneity in principle make subunit interfaces inconsistent targets for the immune response. Here, we investigate how functional stability of Env relates to neutralization sensitivity to V2 bnAbs and V3 crown antibodies that engage subunit interfaces upon binding to unliganded Env. Env heterogeneity was inferred when antibodies neutralized a mutant Env with a plateau of less than 100% neutralization. A statistically significant correlation was found between the stability of mutant Envs and the MPN of V2 bnAb, PG9, as well as an inverse correlation between stability of Env and neutralization by V3 crown antibody, 447-52D. A number of Env-stabilizing mutations and V2 bnAb-enhancing mutations were identified in Env, but they did not always overlap, indicating distinct requirements of functional stabilization versus antibody recognition. Blocking complex glycosylation of Env affected V2 bnAb recognition, as previously described, but also notably increased functional stability of Env. This study shows how instability and heterogeneity affect antibody sensitivity of HIV-1 Env, which is relevant to vaccine design involving its dynamic apex.IMPORTANCE The Env trimer is the only viral protein on the surface of HIV-1 and is the target of neutralizing antibodies that reduce viral infectivity. Quaternary epitopes at the apex of the spike are recognized by some of the most potent and broadly neutralizing antibodies to date. Being that their glycan-protein hybrid epitopes are at subunit interfaces, the resulting heterogeneity can lead to partial neutralization. Here, we screened for mutations in Env that allowed for complete neutralization by the bnAbs. We found that when mutations outside V2 increased V2 bnAb recognition, they often also increased Env stability-of-function and decreased binding by narrowly neutralizing antibodies to the V3 crown. Three mutations together increased neutralization by V2 bnAb and eliminated binding by V3 crown antibodies. These results may aid the design of immunogens that elicit antibodies to the trimer apex.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  envelope; gp120; gp41; human immunodeficiency virus; neutralizing antibodies; protein stability; vaccines

Mesh:

Substances:

Year:  2017        PMID: 28978711      PMCID: PMC5709597          DOI: 10.1128/JVI.01216-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  91 in total

1.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

Authors:  Thaddeus M Davenport; Della Friend; Katharine Ellingson; Hengyu Xu; Zachary Caldwell; George Sellhorn; Zane Kraft; Roland K Strong; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

3.  Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.

Authors:  Ema T Crooks; Tommy Tong; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

6.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

7.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

8.  Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Authors:  Marie Pancera; Syed Shahzad-Ul-Hussan; Nicole A Doria-Rose; Jason S McLellan; Robert T Bailer; Kaifan Dai; Sandra Loesgen; Mark K Louder; Ryan P Staupe; Yongping Yang; Baoshan Zhang; Robert Parks; Joshua Eudailey; Krissey E Lloyd; Julie Blinn; S Munir Alam; Barton F Haynes; Mohammed N Amin; Lai-Xi Wang; Dennis R Burton; Wayne C Koff; Gary J Nabel; John R Mascola; Carole A Bewley; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2013-05-26       Impact factor: 15.369

Review 9.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

10.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

View more
  11 in total

1.  A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.

Authors:  Nitesh Mishra; Shaifali Sharma; Ayushman Dobhal; Sanjeev Kumar; Himanshi Chawla; Ravinder Singh; Bimal Kumar Das; Sushil Kumar Kabra; Rakesh Lodha; Kalpana Luthra
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

2.  Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.

Authors:  Hannah M Schapiro; Mukta D Khasnis; Koree Ahn; Alexandra Karagiaridi; Stephanie Hayden; Maria E Cilento; Michael J Root
Journal:  PLoS Pathog       Date:  2022-05-18       Impact factor: 7.464

3.  Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation.

Authors:  Hanh T Nguyen; Alessandra Qualizza; Saumya Anang; Meiqing Zhao; Shitao Zou; Rong Zhou; Qian Wang; Shijian Zhang; Ashlesha Deshpande; Haitao Ding; Ta-Jung Chiu; Amos B Smith; John C Kappes; Joseph G Sodroski
Journal:  J Virol       Date:  2022-03-28       Impact factor: 6.549

4.  Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.

Authors:  Joseph P Casazza; Evan M Cale; Sandeep Narpala; Galina V Yamshchikov; Emily E Coates; Cynthia S Hendel; Laura Novik; LaSonji A Holman; Alicia T Widge; Preeti Apte; Ingelise Gordon; Martin R Gaudinski; Michelle Conan-Cibotti; Bob C Lin; Martha C Nason; Olga Trofymenko; Shinyi Telscher; Sarah H Plummer; Diane Wycuff; William C Adams; Janardan P Pandey; Adrian McDermott; Mario Roederer; Avery N Sukienik; Sijy O'Dell; Jason G Gall; Britta Flach; Travis L Terry; Misook Choe; Wei Shi; Xuejun Chen; Florence Kaltovich; Kevin O Saunders; Judy A Stein; Nicole A Doria-Rose; Richard M Schwartz; Alejandro B Balazs; David Baltimore; Gary J Nabel; Richard A Koup; Barney S Graham; Julie E Ledgerwood; John R Mascola
Journal:  Nat Med       Date:  2022-04-11       Impact factor: 87.241

5.  Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.

Authors:  Daniel P Leaman; Armando Stano; Yajing Chen; Lei Zhang; Michael B Zwick
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

6.  CpG Frequency in the 5' Third of the env Gene Determines Sensitivity of Primary HIV-1 Strains to the Zinc-Finger Antiviral Protein.

Authors:  Dorota Kmiec; Rayhane Nchioua; Scott Sherrill-Mix; Christina M Stürzel; Elena Heusinger; Elisabeth Braun; Marcos V P Gondim; Dominik Hotter; Konstantin M J Sparrer; Beatrice H Hahn; Daniel Sauter; Frank Kirchhoff
Journal:  mBio       Date:  2020-01-14       Impact factor: 7.867

7.  Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens.

Authors:  Emma T Crooks; Francisco Almanza; Alessio D'Addabbo; Erika Duggan; Jinsong Zhang; Kshitij Wagh; Huihui Mou; Joel D Allen; Alyssa Thomas; Keiko Osawa; Bette T Korber; Yaroslav Tsybovsky; Evan Cale; John Nolan; Max Crispin; Laurent K Verkoczy; James M Binley
Journal:  PLoS Pathog       Date:  2021-10-22       Impact factor: 7.464

8.  Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.

Authors:  Ema T Crooks; Samantha L Grimley; Michelle Cully; Keiko Osawa; Gillian Dekkers; Kevin Saunders; Sebastian Rämisch; Sergey Menis; William R Schief; Nicole Doria-Rose; Barton Haynes; Ben Murrell; Evan Mitchel Cale; Amarendra Pegu; John R Mascola; Gestur Vidarsson; James M Binley
Journal:  PLoS Pathog       Date:  2018-05-02       Impact factor: 6.823

9.  Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein.

Authors:  Vinita R Joshi; Ruchi M Newman; Melissa L Pack; Karen A Power; James B Munro; Ken Okawa; Navid Madani; Joseph G Sodroski; Aaron G Schmidt; Todd M Allen
Journal:  PLoS Pathog       Date:  2020-05-11       Impact factor: 6.823

10.  Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface.

Authors:  Alba Torrents de la Peña; Iván Del Moral Sánchez; Judith A Burger; Ilja Bontjer; Gözde Isik; Dirk Eggink; Marit J van Gils; Rogier W Sanders
Journal:  J Virol       Date:  2021-09-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.